Changes of epigenetic modification and donor cell metabolic status can improve the developmental efficiency of canine-porcine interspecies somatic cell nuclear transfer embryos.
Yan YX., Zhang YH., Wu ZF., Li ZC.
Animal Study, published in Yi Chuan (2025) — summary generated from the PubMed abstract.
Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.
- Level A · Stronger Clinical Evidence
- Level B · Emerging clinical evidence with positive signals
- Level C · Early human research exploring benefits
- Level D · Scientific groundwork from lab and animal studies
- Emerging · Emerging topic under active research
This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.
- Study type
- Animal Study
- Journal
- Yi Chuan (2025)
- Country
- China
- Reported sample size
- —
- Source database
- PubMed
- PMID
- 41407353
- DOI
- 10.16288/j.yczz.25-109
Abstract (original English)
To explore new ways to improve canine cloning efficiency, this study compared the effects of different concentrations and treatment times of glycolysis promoter PS48 and epigenetic modifiers (DNA methylase inhibitor RG108 and histone deacetylase inhibitor Scriptaid) on the developmental ability of canine-porcine interspecies somatic cell nuclear transfer (iSCNT) embryos. The results showed that (1) 5 μmol/L PS48 treatment on canine ear fibroblasts (cEFs) and canine adipose tissue-derived mesenchymal stem cells (cAd-MSCs) for 24 h significantly enhanced subsequent iSCNT embryo development. The cleavage rate, 4-cell stage rate and 8-cell stage rate of iSCNT embryos produced from PS48-treated cEFs were significantly higher than those of control iSCNT embryos (46.90±1.64% vs 13.30±1.61%, 32.30±1.55% vs 8.26±0.88%, and 10.62±1.68% vs 5.50±0.84%; P <0.05). The cleavage and 4-cell stage rates of iSCNT embryos generated from PS48-treated cAd-MSCs were significantly higher than those of control iSCNT embryos (49.51±3.00% vs 31.25±2.73%, 26.21±2.08% vs 15.18±1.58%; P <0.05). (2) Treatment of cEFs and cAd-MSCs with 20 μmol/L RG108 for 48 h had no significant effect on the developmental efficiency of iSCNT embryos. Treatment of cEFs and cAd-MSCs with 0 nmol/L, 400 nmol/L, 500 nmol/L and 600 nmol/L Scriptaid for 24 h had no significant effect on the developmental efficiency of iSCNT embryos
What this study does not prove
- • This study does not prove SVF is an approved treatment or a replacement for standard care.
- • This is preclinical work; animal or laboratory results cannot be applied to humans.
Evidence level
Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.
How we grade evidenceBrowse all related research
Filter the research library by this study's title keywords, author, or publication year.